Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivuxolimab + utomilumab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are investigational, fully humanized IgG2 monoclonal antibodies developed by Pfizer for the treatment of advanced cancers. Ivuxolimab targets OX40, a receptor on memory T-cells, promoting their division and survival while suppressing regulatory T-cell activity to enhance anti-tumor immune responses. Utomilumab targets 4-1BB (CD137), a costimulatory receptor on activated T-cells and natural killer cells, stimulating these immune cells to augment anti-tumor activity. The combination is designed to synergistically activate the immune system against tumor cells. Both agents have demonstrated safety and preliminary antitumor activity in early-phase clinical trials for advanced solid tumors[1][2][3][5].
- Other names
- ivuxolimab + utomilumab
02
Targets
TNFRSF9 (CD137 extracellular domain)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on ivuxolimab + utomilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivuxolimab + utomilumab.